* Context.-Overexpression of human epidermal growth factor receptor 2 (HER2) is an adverse prognostic parameter for patients with breast cancer. Patients with HER2- positive tumors are, however, likely to gain significant benefit from targeted therapy with trastuzumab. Four largescale trials have assessed the efficacy and safety of adjuvant trastuzumab. In all 4 trials, disease-free survival and overall survival were significantly improved with adjuvant trastuzumab (36%-52% and 33%-41%, respectively), and improvements were observed in all patient subgroups.

Objective.-To describe, in detail, the clinical benefits of using trastuzumab in the adjuvant setting, and to emphasize the importance ...

Related newspaper, magazine, and journal articles:

;

See all results. Or, try our Advanced Search.

We're searching over:

• 60 million articles
• 3,500 publications